REQUEST A DEMO
Total
USD $0.00
Search more companies

Ensol Biosciences Inc. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: Ensol Biosciences Inc. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved in the development and sale of drugs for degenerative disc disease (DDD), osteoarthritis, triple negative breast cancer (TNBC), Alzheimer s disease (AD) and type I diabetes. In addition, it also produces and sells drugs for animal and provides bio big data analysis services. The drugs for Animal include drugs for animal osteoarthritis, as well as animal anticancer, among others. The bio big data analysis services are provided by knowledge-based in silico drug discovery (KISDD) platform and Ensol trans-omics network system (ETONS). The Company was founded on February 20, 2001 and its shares are listed on KOREA NEW EXCHANGE(KONEX) on September 10, 2018.

Headquarters
51, Techno 10-Ro, Yuseong-Gu
Daejeon; Daejeon;

Contact Details: Purchase the Ensol Biosciences Inc. report to view the information.

Website: http://www.ensolbio.co.kr

Basic Information
Total Employees:
Purchase the Ensol Biosciences Inc. report to view the information.
Outstanding Shares:
Purchase the Ensol Biosciences Inc. report to view the information.
Financial Auditors:
Purchase the Ensol Biosciences Inc. report to view the information.
Incorporation Date:
December 05, 2025
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
(주)비손사이언스
100%
Company Performance
Financial values in the chart are available after Ensol Biosciences Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
712.61%
Total operating revenue
624.87%
Operating profit (EBIT)
50.87%
EBITDA
49.8%
Net Profit (Loss) for the Period
-56.91%
Total assets
-19.58%
Total equity
-307.42%
Operating Profit Margin (ROS)
5721.81%
Net Profit Margin
5165.7%
Return on Equity (ROE)
-127.46%
Debt to Equity Ratio
108.32%
Quick Ratio
-0.27%
Cash Ratio
-0.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?